Autres langues Genmab A/S Nasdaq

Actions

GMAB

US3723032062

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 18/06/2026			Varia. 5j.	Varia. 1 janv.
25,27 ^USD	-0,47 %		+0,76 %	-17,95 %

15/06	Valeurs nordiques en Amérique du Nord : Ericsson recule de 1,4 %	FW
13/06	Genmab annonce des taux de réponse élevés pour l'epcoritamab en monothérapie et en association chez les patients âgés atteints d'un lymphome diffus à grandes cellules B nouvellement diagnostiqué	CI

Autres langues

17/06	Genmab A/S : has published its Articles of Association
16/06	Capital Increase in Genmab as a Result of Employee Warrant Exercise
16/06	Capital Increase in Genmab as a Result of Employee Warrant Exercise
15/06	Major Shareholder Announcement
15/06	Major Shareholder Announcement
15/06	Genmab A/S : has published its Articles of Association
13/06	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
13/06	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
13/06	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
11/06	Grant of Restricted Stock Units and Warrants to Employees in Genmab
11/06	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits
11/06	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
11/06	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
11/06	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients
02/06	U.S. Futures Slip, European Stocks Edge Up
01/06	U.S. Futures Edge Up, European Stocks Mixed
29/05	Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
22/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology Annual Meeting and the European Hematology Association 2026 Congress
21/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
21/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
18/05	Genmab Maintained at Buy as BofA Notes Upcoming Key Catalysts
13/05	Genmab A/S : Articles of association dated May 12, 2026 – English
13/05	Genmab A/S : has published its Articles of Association
12/05	Capital Increase in Genmab as a Result of Employee Warrant Exercise
11/05	Genmab - Major Shareholder Announcement